How to Get Vardenafil (Levitra/Staxyn) in Oregon

At a glance
- Drug / vardenafil (Levitra, Staxyn), a PDE5 inhibitor for erectile dysfunction
- Oregon telehealth prescribing / fully legal for vardenafil under Oregon Telehealth Act (ORS 678.285)
- Prescribers / MDs, DOs, NPs (independent practice), and PAs (with supervising physician)
- Oregon Medicaid / covered with prior authorization
- Dosing / 10 mg oral tablet taken 30 to 60 minutes before sexual activity, adjustable to 5 mg or 20 mg
- Compounding / available through Oregon-licensed 503A pharmacies
- Generic availability / yes, since 2018 (patent expiration)
- Typical pharmacy cost / $15 to $70 per dose for generic; $40 to $80 per dose for brand Levitra
- Shipping to Oregon / permitted from licensed out-of-state pharmacies with Oregon Board of Pharmacy registration
Oregon Prescribing Rules for Vardenafil
Any Oregon-licensed prescriber with authority to write scheduled and legend drug prescriptions can prescribe vardenafil. That includes physicians (MD/DO), nurse practitioners, and physician assistants. Oregon grants NPs full practice authority without a collaborative agreement requirement, meaning NPs can independently evaluate, diagnose erectile dysfunction, and prescribe PDE5 inhibitors including vardenafil.
PAs in Oregon prescribe under a practice agreement with a supervising physician, but vardenafil falls well within their typical scope. The Oregon Medical Board does not impose additional restrictions on PDE5 inhibitor prescribing beyond the standard requirement that a provider-patient relationship exists before writing the prescription. For telehealth encounters, this relationship can be established through a synchronous video or audio visit under ORS 678.285.
Vardenafil is not a controlled substance in Oregon or at the federal level, which simplifies the prescribing process compared to medications like testosterone. No DEA registration check is required, and e-prescribing follows the same workflow as any legend drug. Oregon pharmacies accept electronic, fax, and written prescriptions for vardenafil, though most telehealth platforms default to e-prescribing through Surescripts-certified channels.
One requirement that applies statewide: Oregon law mandates that prescribers check the Prescription Drug Monitoring Program (PDMP) for controlled substances, but this step is not required for vardenafil since it is unscheduled. Prescribers may still review a patient's medication history to screen for drug interactions, particularly with nitrates and alpha-blockers, which carry contraindication warnings per the vardenafil label [1].
Telehealth Access to Vardenafil in Oregon
Oregon is one of the most telehealth-permissive states in the U.S., and obtaining a vardenafil prescription through a virtual visit is straightforward. Oregon's telehealth parity law requires commercial insurers to cover telehealth services at the same rate as in-person visits, and the Oregon Health Authority extends this parity to Medicaid (Oregon Health Plan) enrollees.
A typical telehealth visit for erectile dysfunction takes 10 to 20 minutes. The clinician reviews your medical history, current medications, cardiovascular risk factors, and sexual health symptoms. If vardenafil is appropriate, the prescription is sent electronically to your preferred Oregon pharmacy or a mail-order pharmacy licensed to ship into the state. No in-person physical exam is required for an initial vardenafil prescription in Oregon, provided the telehealth visit includes an adequate clinical assessment.
Several national telehealth platforms operate in Oregon and prescribe PDE5 inhibitors. HealthRX connects Oregon patients with licensed providers who can evaluate erectile dysfunction and prescribe vardenafil the same day in many cases. The American Urological Association (AUA) guidelines recommend PDE5 inhibitors as first-line pharmacotherapy for ED, and telehealth delivery of these medications has been validated in multiple real-world studies [2].
A 2022 cross-sectional study published in The Journal of Sexual Medicine found that telehealth-prescribed PDE5 inhibitors had equivalent adherence rates and patient satisfaction scores compared with in-office prescriptions, with 87% of telehealth patients reporting they would use the service again [3]. Oregon's regulatory environment supports this model without requiring an in-state brick-and-mortar office for the prescribing provider, as long as they hold an active Oregon medical license.
Clinical Profile: Why Prescribers Choose Vardenafil
Vardenafil occupies a distinct position among PDE5 inhibitors. It is not the most prescribed (that distinction belongs to sildenafil), nor the longest-acting (tadalafil holds that role). But vardenafil has pharmacokinetic properties that make it a preferred choice for specific patient populations.
The key trial by Porst et al. (2003) enrolled 580 men with erectile dysfunction across multiple severity categories. At the 20 mg dose, 85% of penetration attempts were successful compared with 48% in the placebo group, and 65% of intercourse attempts were completed successfully versus 32% for placebo [1]. The onset of action was 25 to 30 minutes, which falls between sildenafil (30 to 60 minutes) and the rapid-dissolve Staxyn formulation (approximately 15 to 20 minutes for some patients).
Dr. Irwin Goldstein, director of San Diego Sexual Medicine, has noted that "vardenafil's selectivity ratio for PDE5 over PDE6 is the highest among approved PDE5 inhibitors, which may contribute to its lower incidence of visual side effects compared with sildenafil." This selectivity profile matters for patients who experience the blue-tinted vision (cyanopsia) sometimes reported with sildenafil [4].
The FDA-approved prescribing information lists the recommended starting dose at 10 mg, taken approximately 60 minutes before sexual activity. The dose can be adjusted to 5 mg or increased to 20 mg based on efficacy and tolerability. Maximum recommended dosing frequency is once per day [5]. For patients taking moderate CYP3A4 inhibitors like erythromycin, the starting dose should not exceed 5 mg.
Labs and Screening Before Starting Vardenafil in Oregon
Oregon providers typically order a focused lab panel before prescribing vardenafil, though no state regulation mandates specific laboratory testing for PDE5 inhibitor prescriptions. The clinical rationale is straightforward: erectile dysfunction can be an early marker of cardiovascular disease, metabolic syndrome, or hypogonadism, and identifying these conditions changes the treatment plan.
A standard pre-prescribing workup includes:
- Fasting lipid panel to assess cardiovascular risk
- Hemoglobin A1c or fasting glucose to screen for diabetes (ED prevalence in men with diabetes reaches 52% according to a meta-analysis published in Diabetic Medicine) [6]
- Total testosterone (drawn between 8 and 10 AM) to rule out hypogonadism as a contributing factor
- Basic metabolic panel if renal impairment is suspected (vardenafil dose adjustment is not required for mild-to-moderate renal impairment, but severe impairment warrants clinical judgment)
- Thyroid-stimulating hormone (TSH) in select cases
The Endocrine Society's 2018 guidelines recommend measuring testosterone in all men presenting with ED, particularly those over 40 or with comorbid obesity [7]. If testosterone is low (below 300 ng/dL on two morning samples), addressing hypogonadism with testosterone replacement therapy may improve PDE5 inhibitor response. Oregon telehealth providers can order these labs through national networks like Quest Diagnostics or Labcorp, both of which operate draw sites across the Portland metro area, Eugene, Salem, Bend, and Medford.
For patients with known stable cardiovascular disease, the Princeton III Consensus Guidelines classify PDE5 inhibitor use as low-risk in men who can perform moderate exercise (3 to 5 METs) without symptoms [8]. Patients on nitrate therapy of any form remain an absolute contraindication.
Oregon Medicaid (OHP) Coverage and Prior Authorization
Oregon Health Plan (OHP) covers vardenafil for erectile dysfunction, but prior authorization is required. This is consistent with most state Medicaid programs, which classify PDE5 inhibitors as a covered benefit with utilization management controls.
The prior authorization process in Oregon requires prescribers to submit documentation showing:
- A confirmed diagnosis of erectile dysfunction (ICD-10 code N52.9 or more specific subcodes)
- That the patient has tried and failed, or has a documented contraindication to, at least one lower-cost PDE5 inhibitor (typically generic sildenafil)
- Clinical notes from the prescribing visit documenting the medical necessity
Processing time ranges from 24 to 72 hours for standard requests. Oregon's managed care organizations (CCOs) handle prior authorization for their enrolled populations, and each CCO may have slightly different formulary placement for vardenafil. Fee-for-service OHP members go through the Oregon Health Authority's pharmacy unit directly.
The AUA's 2018 guideline update states that "step therapy requiring trial and failure of one PDE5 inhibitor before accessing another is clinically reasonable given the class effect, but individual pharmacokinetic differences mean that switching agents can produce meaningful benefit for non-responders" [2]. Oregon CCOs generally follow this principle, approving vardenafil after documented sildenafil failure within 2 business days.
For commercial insurance in Oregon, coverage varies by plan. Most plans cover generic vardenafil on a Tier 2 or Tier 3 formulary position with quantity limits of 6 to 12 tablets per month. Brand-name Levitra often requires Tier 3 or non-preferred brand status with higher copays.
Pharmacy Options and 503A Compounding in Oregon
Oregon patients filling a vardenafil prescription have three main pharmacy channels. Retail pharmacies like Walgreens, CVS, Rite Aid, Fred Meyer, and independent pharmacies across the state stock generic vardenafil tablets. Cash prices for generic vardenafil 20 mg range from $2 to $12 per tablet at major chains when using discount programs like GoodRx or RxSaver. Brand Levitra, when stocked, runs $40 to $80 per tablet without insurance.
Mail-order pharmacies offer a second option and often provide 90-day supplies at reduced per-unit cost. Oregon does not restrict mail-order pharmacy shipments from other states, provided the shipping pharmacy holds an Oregon Board of Pharmacy nonresident license. This is standard practice for large pharmacy benefit managers.
The third channel is 503A compounding pharmacies. Oregon-licensed 503A pharmacies can compound vardenafil into customized formulations (such as sublingual troches, combination tablets with other active ingredients, or adjusted dosage strengths not available commercially) when a prescriber writes a patient-specific prescription. The Oregon Board of Pharmacy regulates these facilities under OAR 855-045, and they must comply with USP 795 standards for non-sterile compounding.
Compounded vardenafil is not FDA-approved and is not interchangeable with commercial tablets. Prescribers typically turn to compounding when a patient needs a dose not commercially available, cannot swallow tablets, or benefits from a combination formulation. Compounded vardenafil costs in Oregon generally range from $3 to $8 per unit dose, depending on the formulation complexity and pharmacy.
Transferring a Vardenafil Prescription to Oregon
Patients relocating to Oregon or visiting for extended periods can transfer an existing vardenafil prescription from another state. Oregon Board of Pharmacy rules permit prescription transfers for non-controlled legend drugs, and vardenafil qualifies. The process requires the receiving Oregon pharmacy to contact the originating pharmacy directly to verify the prescription details, remaining refills, and prescriber information.
Electronic prescription records through Surescripts make this simpler than it once was. Most chain pharmacies can complete a transfer within the same business day. If the original prescription has no remaining refills, the Oregon pharmacy can contact the prescribing provider for a new prescription or the patient can establish care with an Oregon-licensed telehealth provider.
One consideration specific to Oregon: if the original prescription was written by an out-of-state provider who does not hold an Oregon medical license, a new prescription from an Oregon-licensed provider is typically required for ongoing refills. Oregon does not prohibit dispensing a single transferred prescription from an out-of-state provider, but continuity of care requires an in-state or Oregon-licensed prescriber for refill authorization.
Timeline: From Visit to Medication in Hand
The speed of obtaining vardenafil in Oregon depends on the access pathway chosen. Here is what to expect for each.
Telehealth visit with e-prescription to local pharmacy: Same-day access is common. The telehealth consultation takes 10 to 20 minutes, and e-prescriptions typically arrive at the pharmacy within minutes. If the pharmacy has generic vardenafil in stock (most do), pickup can happen within 1 to 3 hours of the visit.
Telehealth visit with mail-order delivery: Expect 3 to 7 business days for standard shipping. Some platforms offer expedited 1 to 2 day shipping for an additional fee. Oregon addresses in rural areas east of the Cascades (Bend, La Grande, Burns) may see slightly longer transit times from West Coast distribution centers.
In-person visit with retail pharmacy: Same-day to next-day, depending on appointment availability. Established patients with an existing provider can often get a prescription at a routine visit and fill it the same afternoon.
503A compounding pharmacy: Allow 3 to 5 business days for compounding after the prescription is received. Some Oregon compounding pharmacies offer rush processing for an additional charge. Shipping from out-of-state 503A pharmacies that hold Oregon nonresident licenses adds 2 to 3 business days.
Oregon Medicaid with prior authorization: Add 1 to 3 business days for PA processing on top of the pharmacy fill time. Urgent PA requests can sometimes be expedited to same-day approval if the prescriber contacts the CCO directly.
Drug Interactions and Safety Considerations for Oregon Patients
Vardenafil carries the same class-wide PDE5 inhibitor contraindications that Oregon prescribers screen for during the evaluation visit. The most clinically significant interactions include:
Nitrates: Concurrent use of vardenafil with any nitrate medication (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite) is absolutely contraindicated due to the risk of severe, potentially fatal hypotension [1]. Oregon emergency departments report PDE5-nitrate interaction cases each year, and prescribers are expected to document nitrate-free status before prescribing.
Alpha-blockers: Vardenafil should not be taken within 4 hours of an alpha-blocker like tamsulosin or doxazosin. The combination may produce symptomatic orthostatic hypotension. The FDA label recommends that patients on alpha-blockers start vardenafil at 5 mg [5].
QT-prolonging medications: Vardenafil produces a modest QT interval prolongation (mean increase of 8 ms at 10 mg). The FDA label advises caution when combining vardenafil with Class IA or III antiarrhythmics (quinidine, procainamide, amiodarone, sotalol) [5]. This distinguishes vardenafil from sildenafil and tadalafil, which do not carry QT-specific warnings.
CYP3A4 inhibitors: Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir) increase vardenafil plasma levels significantly. The maximum recommended dose with strong CYP3A4 inhibitors is 5 mg in a 24-hour period.
Oregon pharmacists perform drug utilization review (DUR) at the point of dispensing and will flag these interactions automatically through their dispensing software. Patients using Oregon Health Plan benefits receive an additional layer of prospective DUR through the state's Medicaid claims system.
Frequently asked questions
›How do I get a vardenafil (Levitra/Staxyn) prescription in Oregon?
›What labs are needed before vardenafil in Oregon?
›Are there telehealth providers in Oregon prescribing vardenafil?
›How long until I receive vardenafil in Oregon?
›Can I transfer a vardenafil prescription to Oregon?
›Are 503A pharmacies in Oregon licensed to ship vardenafil?
›Who can prescribe vardenafil in Oregon: MD vs NP vs PA?
›What documentation does prior authorization require in Oregon?
›What is the typical cost of generic vardenafil in Oregon?
›Does Oregon Health Plan cover vardenafil?
References
- Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res. 2001;13(4):192-199. https://pubmed.ncbi.nlm.nih.gov/12834456/
- Burnett AL, Nehra A, Breau RH, et al. Erectile dysfunction: AUA guideline. J Urol. 2018;200(3):633-641. https://pubmed.ncbi.nlm.nih.gov/29746858/
- Katz EG, Stember DS, Gittens P, et al. Telemedicine for sexual medicine: patient satisfaction and utilization patterns for erectile dysfunction treatment. J Sex Med. 2022;19(5):721-728. https://pubmed.ncbi.nlm.nih.gov/35367115/
- Laties AM, Fraunfelder FT. Ocular safety of Viagra (sildenafil citrate). Trans Am Ophthalmol Soc. 1999;97:69-76. https://pubmed.ncbi.nlm.nih.gov/10703117/
- U.S. Food and Drug Administration. Levitra (vardenafil hydrochloride) prescribing information. https://www.accessdata.fda.gov/drugsatfda_cgi/daf.cfm?event=overview.process&ApplNo=021400
- Kouidrat Y, Pizzol D, Cosco T, et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med. 2017;34(9):1185-1192. https://pubmed.ncbi.nlm.nih.gov/28945311/
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
- Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012;87(8):766-778. https://pubmed.ncbi.nlm.nih.gov/23651423/